by Raynovich Rod | Sep 29, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… See Caution 9/29 Update-2…See Rayno Biobeat for updates after Trump Rally. For overweighting biotechs in a portfolio consider XBI instead of IBB to get mid and small cap exposure. ——– Rayno Portfolio Outperforms the Market...
by Raynovich Rod | Sep 26, 2016 | Biopharmaceuticals
Update-2… 9/29 Caution on Biotech-Major Sell-Off with IBB off 3.12% The market had a bad day today hit by Wells Fargo (WFC) Congressional hearings and paranoia about Deutsche Bank AG (DB). Unrelated to this news was a major sell-off in biotech stocks with...
by Raynovich Rod | Sep 22, 2016 | Biopharmaceuticals
Biotech ETFs Are Having A Strong Quarter and Offer Good Investment Options On July 20 we did a review of active funds vs biotech ETFs in the biotechnology/life science sector just after the BREXIT lows. At that time biotech ETFs and broadly diversified funds beat the...
by Raynovich Rod | Sep 20, 2016 | Biopharmaceuticals
Update-1…FED Goes on Hold with Rate Increase Likely by Year End Three on FOMC dissented wanting a rate hike this round. Market immediately rallied with NASDAQ up 1.03% at close; S&P and Dow also rally. Biotechs like low i rates:IBB up 0.62% to $297, XBI up...
by Raynovich Rod | Sep 15, 2016 | Biopharmaceuticals
Biopharma Stocks Breeze through ‘Quadruple Witching Day”…9/16 Healthcare stocks (XLV) were one of the leading sectors on a down day up a tiny bit to $72. The IBB held, up 0.57% to the $291 mark and up 4.75% for the week. The more volatile XBI was a...
by Raynovich Rod | Sep 12, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… 9/13… Hard to Call Next Move: Macro and i Rates Rule The market was rattled at the opening with the IEA news on cuts in the demand forecast for crude which dropped 2.33%. Subsequently FED hike fears returned causing more volatility with stocks...
by Raynovich Rod | Sep 8, 2016 | Biopharmaceuticals
Update-2…Market rallies Monday after 2% sell-off on Friday IBB held support at $280, up 1.9% today to 284 as of mid-morning . Mid-caps and large caps strong. —— Update-1… FED Rate Increase Fear Sparks Sell-Off NASDAQ down 1.14%, 10 Year Bond...
by Raynovich Rod | Sep 6, 2016 | Clinical Diagnostics and Tools
M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of...